Innovent Biologics, Inc.
IVBXF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.21 | -0.26 | 0.62 | -0.03 |
| FCF Yield | 0.17% | 2.26% | -1.65% | 0.45% |
| EV / EBITDA | 116.39 | -216.32 | -203.88 | -65.69 |
| Quality | ||||
| ROIC | 3.65% | -0.08% | -4.31% | -5.53% |
| Gross Margin | 77.26% | 75.91% | 72.31% | 70.75% |
| Cash Conversion Ratio | 0.38 | 5.04 | 0.55 | -0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 42.77% | 47.28% | 82.96% | 116.74% |
| Free Cash Flow Growth | -82.92% | 235.12% | -467.21% | 120.41% |
| Safety | ||||
| Net Debt / EBITDA | -5.98 | 20.21 | 19.35 | 8.67 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.20 | 1.60 | 1.59 | 1.06 |
| Cash Conversion Cycle | 72.30 | 57.52 | 69.81 | 78.12 |